{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:23:51Z","timestamp":1772709831421,"version":"3.50.1"},"reference-count":67,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1517\/14656566.2014.909409","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T00:59:20Z","timestamp":1398214760000},"page":"1029-1042","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia"],"prefix":"10.1517","volume":"15","author":[{"given":"Larry","family":"Alphs","sequence":"first","affiliation":[{"name":"Therapeutic Area Leader Psychiatry, Janssen Scientific Affairs, LLC","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A","family":"Bossie","sequence":"additional","affiliation":[{"name":"Analyses & Publications, Medical Affairs, Central Nervous System, Janssen Scientific Affairs, LLC","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Jing","family":"Fu","sequence":"additional","affiliation":[{"name":"CNS Clinical Development, Janssen Scientific Affairs, LLC","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Ma","sequence":"additional","affiliation":[{"name":"Clinical Biostatistics, Janssen Research & Development, LLC","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Kern Sliwa","sequence":"additional","affiliation":[{"name":"Scientific Intelligence, Janssen Scientific Affairs, LLC","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,4,22]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apnu.2011.03.008"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007078"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1976.01770040053010"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1205"},{"key":"e_1_3_2_7_1","first-page":"S5","article-title":"The primary and secondary symptoms of schizophrenia: current and future management","volume":"10","author":"Nasrallah HA","year":"2011","unstructured":"Nasrallah HA. The primary and secondary symptoms of schizophrenia: current and future management. Suppl Curr Psychiatry 2011;10:S5-9","journal-title":"Suppl Curr Psychiatry"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760130049008"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(99)00111-0"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.140.4.470"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S20657"},{"key":"e_1_3_2_12_1","first-page":"CD008296","article-title":"Paliperidone palmitate for schizophrenia","volume":"6","author":"Nussbaum AM","year":"2012","unstructured":"Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev 2012;6:CD008296","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/11208640-000000000-00000"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.07081221"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005987"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12r08167"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08440"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs150"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.02.003"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.111"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2008.12.002"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2008.59.3.315"},{"key":"e_1_3_2_23_1","first-page":"23","article-title":"A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia","volume":"7","author":"Macfadden W","year":"2010","unstructured":"Macfadden W, Ma YW, Thomas HJ, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry 2010;7:23-31","journal-title":"Psychiatry"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.105.017020"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835b091f"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/764769"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.11.020"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-221"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.10.022"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.195.52.s13"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712001277"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318272688b"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109106914"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-013-0105-7"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.137"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/11316870-000000000-00000"},{"key":"e_1_3_2_39_1","author":"Janssen Pharmaceuticals, Inc","year":"2012","unstructured":"Janssen Pharmaceuticals, Inc. INVEGAR SUSTENNAR (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Janssen Pharmaceuticals, Inc., Titusville, NJ; 2012","journal-title":"INVEGAR SUSTENNAR (paliperidone palmitate) extended-release injectable suspension, for intramuscular use"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181dd3103"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.79"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990988"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110372817"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.10.026"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003798927"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.595000"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-79"},{"key":"e_1_3_2_48_1","unstructured":"Sliwa JK Bossie CA Fu DJ et al. Onset of efficacy on specific symptoms domains with long-acting injectionable palperidone palmitate in subjects with schizophrenia. Poster presented at: 14th International Congress on Schizophrenia Research; 21 \u2013 25 April 2013; Orlando FL"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.11.008"},{"key":"e_1_3_2_50_1","first-page":"26","article-title":"A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia","volume":"8","author":"Gopal S","year":"2011","unstructured":"Gopal S, Pandina G, Lane R, et al. A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci 2011;8:26-33","journal-title":"Innov Clin Neurosci"},{"key":"e_1_3_2_51_1","unstructured":"Alphs L Fu DJ Sliwa JK et al. Onset of efficacy in schizophrenia symptom domains with long-acting injectable paliperidone palmitate vs oral risperidone. Poster presented at: American Psychiatric Association 166th Annual Meeting; 18 \u2013 22 May 2013; San Francisco CA"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05284yel"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-261"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721060-00001"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3280c28424"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02176.x"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.12.2382"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0703"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0b013e31816a62a0"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198205273062103"},{"key":"e_1_3_2_61_1","unstructured":"Weiden PJ Roma RS Velligan DI et al. The challenge of offering long acting antipsychotic therapies: A discourse analysis of psychiatrist recommendations of injectable therapy to patients with schizophrenia. Presented at the 2011 US Psychiatric and Mental Health Congress; 7 \u2013 10 November 2011; Las Vegas NV"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11414-013-9329-z"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.751025"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.01.022"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001738"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn110"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11r07539"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833948fa"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S54051"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.2014.909409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:41:53Z","timestamp":1772707313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.2014.909409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,22]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1517\/14656566.2014.909409"],"URL":"https:\/\/doi.org\/10.1517\/14656566.2014.909409","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}